From May 30 to June 3, 2025, the largest and most prestigious global oncology conference—the American Society of Clinical Oncology (ASCO) Annual Meeting—will be held at the McCormick Place Convention Center in Chicago, USA. Escugen’s TROP2 ADC product ESG401 will present two research findings at this year’s conference. This marks the third consecutive year that the clinical progress of ESG401 has been selected for presentation at the ASCO Annual Meeting.

On May 13, 2025, the clinical research results of ESG401, a TROP2 ADC drug developed by Escugen Biotechnology for treating brain metastasis in patients with advanced HER2-negative breast cancer, were officially published online in ESMO Open, a well-known international medical journal hosted by the European Society for Medical Oncology (ESMO). The paper is titled "Novel TROP2 antibody–drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option." The article reports the efficacy and safety data of ESG401 in HER2-negative breast cancer patients with brain metastasis.